CurrentHealth NetPolicy Reference Number: CP.PHAR.216

Factor VIII/von Willebrand Factor Complex (Human Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant Vonvendi)

Clinical coverage and prior authorization criteria for Alphanate, Humate-P, Wilate, and Vonvendi for treatment of Hemophilia A and von Willebrand disease across Commercial, HIM, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyFactor VIII/von Willebrand Factor Complex (Human Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant Vonvendi)

Policy CodePolicy Reference Number: CP.PHAR.216

Change TypeRevisions and clarifications (DDAVP trial, prophylaxis criteria, approval durations)

Effective Date05.01.16

Next Review Date

Key ActionProvider must submit documentation (office notes, labs, weight, dosing) supporting diagnosis and that all applicable approval criteria are met.

SourceLink

POLICY UPDATE CHANGES

Revised desmopressin acetate (DDAVP) trial requirement to apply only for age ≥ 2 years.

Clarified that FVIII activity level or documentation of bleed history requirement applies only to new starts of routine prophylactic Wilate.

Initial and continued authorization durations changed for prophylaxis for Medicaid/HIM (to 12 months) and Commercial (to 6 months or to member renewal date).

3Lines of business

4Products referenced

12Approval duration (Medicaid/HIM prophylaxis, months)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria

Initial Approval Criteria - Congenital Hemophilia A

Covered when ALL of the following are met:

ALL of the following

Diagnosis of congenital hemophilia A (factor VIII deficiency)
Requested product is Alphanate, Humate-P, or Wilate
Prescribed by or in consultation with a hematologist
Requested use (one of)
- Control or prevention of bleeding episodes
- Perioperative management (Alphanate only)
- Routine prophylaxis to reduce frequency of bleeding episodes (Wilate only)
If request is for routine prophylaxis (Wilate) and member is new to Wilate
- Member has severe hemophilia (FVIII level < 1%)
- Member has experienced at least one serious spontaneous bleed (see Appendix D for definition)
For age ≥ 2 years AND FVIII coagulant activity levels > 5%: failure of desmopressin acetate (DDAVP) unless contraindicated, adverse effects, or unavailable
Step therapy requirement waived for Illinois HIM requests per IL HB 5395 (effective 1/1/2026)
Documentation of member's current body weight (kg)
Dose does not exceed the FDA approved maximum recommended dose for the indication
Refer to product-specific maximums (e.g., Wilate maximum 150 IU/kg/day for hemophilia A; Wilate max 60 IU/kg/day for VWD; Alphanate max 100 IU/kg/day)

Initial Approval Criteria - Von Willebrand Disease (VWD)

Covered when ALL of the following are met:

ALL of the following

Diagnosis of von Willebrand disease (VWD)
Prescribed by or in consultation with a hematologist
For age ≥ 2 years AND VWD type 1 or 2 (except type 2B): failure of desmopressin acetate (DDAVP) unless contraindicated, adverse effects, or unavailable
Step therapy bypass for IL HIM per IL HB 5395 applies to Vonvendi and Wilate as of 1/1/2026
Requested use (one of)
- Treatment of bleeding episodes (Humate-P, Vonvendi, Wilate only)

Initial Approval Criteria - Other diagnoses/indications

Covered only if either 1 or 2 below apply:

ANY of the following

If drug label recently changed within last 6 months and policy not updated, follow appropriate no-coverage or non-formulary policy listed (see CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16)
If requested use is not listed under section III and label change does not apply, refer to off-label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53)

Continued Therapy (All Indications in Section I)

Covered when ALL of the following are met:

ALL of the following

ANY of the following
- Member currently receiving medication via Centene benefit or previously met initial approval criteria
- Member currently receiving medication and enrolled in state/product with continuity of care regulations (see state addendums CC.PHARM.03A and CC.PHARM.03B)
Member is responding positively to therapy
If request is for dose increase
- Documentation of member's current body weight in kg (if requesting a higher dose than previously requested)

Diagnoses/Indications Not Authorized

Not covered when:

ALL of the following

Non-FDA approved indications that are not addressed in this policy, unless sufficient documentation exists per off-label use policy or evidence of coverage (see CP.CPA.09, HIM.PA.154, CP.PMN.53)

Relevant Billing Codes

HCPCS - Products referencedHCPCS

J7183	Injection, von Willebrand factor complex (human), Wilate, 1 IU vWF:RCo
J7186	Injection, antihemophilic FVIII/von Willebrand factor complex (human), per FVIII i.u. (Alphanate)
J7187	Injection, von Willebrand factor complex (Humate-P), per IU VWF:RCO
J7179	Injection, von Willebrand factor (recombinant), (Vonvendi), per 1 IU vWF:rco

Required Provider Actions and Billing Rules

Prior Authorization

Prior authorization required

Provider must submit documentation (such as office chart notes, laboratory results, current body weight in kg, and dosing information) that supports the member’s diagnosis and that all applicable approval criteria are met prior to coverage.

J7183
J7186
J7187
J7179

Documentation Required

Weight documentation

Document the member’s current body weight in kilograms for all initial authorization requests and when requesting a higher dose on continued therapy.

Clinical Thresholds and Key Definitions

Thresholds - key values

FVIII level for severe hemophilia< 1% (severe hemophilia definition used for Wilate prophylaxis new starts)

FVIII coagulant activity threshold for DDAVP trial applicability> 5% (DDAVP trial required for age ≥ 2 years when FVIII > 5%)

Prophylaxis approval duration - Medicaid/HIM12 months for prophylaxis (Medicaid/HIM)

Definitions

Serious bleeding episodeBleeds in intracranial; neck/throat; gastrointestinal; joints (hemarthrosis); deep compartment muscles (e.g., iliopsoas, calf, forearm); or mucous membranes of mouth, nose, and genitourinary tract.

Spontaneous bleedA bleeding episode occurring without apparent cause and not the result of trauma.

Clinical Background

Alphanate, Humate‑P, and Wilate are plasma‑derived factor VIII (FVIII)/von Willebrand factor (vWF) complexes indicated for treatment of Hemophilia A and certain presentations of von Willebrand disease (VWD). Alphanate and Humate‑P are used for control and prevention of bleeding episodes and perioperative management; Wilate is indicated for on‑demand treatment, perioperative management, and for routine prophylaxis in adolescents and adults to reduce bleed frequency. Vonvendi is a recombinant vWF product approved for on‑demand treatment and perioperative management in adults and pediatrics, and for routine prophylaxis in adults (with pediatric extensions reflected in recent label updates). (Source: product listing and FDA‑approved indications.)

Desmopressin acetate (DDAVP) is an alternative therapy for selected patients with adequate FVIII activity or certain VWD types (type 1 or 2 except 2B). Per policy, for patients aged ≥ 2 years with FVIII coagulant activity > 5% (or VWD type 1/2 where applicable), a trial of DDAVP is required prior to coverage of the referenced factor/vWF products unless DDAVP is contraindicated, causes clinically significant adverse effects, or an appropriate formulation is unavailable. An Illinois Health Insurance Marketplace (HIM) step‑therapy bypass applies for certain requests per IL HB 5395. (Source: DDAVP dosing/role and policy step‑therapy criteria.)

Prior authorization requires documentation supporting the diagnosis, prescribing by or in consultation with a hematologist, current body weight (kg) for initial requests (and when requesting a higher dose on continued therapy), and that dosing does not exceed FDA‑approved maximums for the indication. For Wilate routine prophylaxis new starts, the policy specifies additional eligibility thresholds (e.g., severe hemophilia defined as FVIII < 1% or at least one serious spontaneous bleed). These requirements and thresholds must be met to authorize coverage. (Source: policy criteria, weight and dosing documentation, and thresholds.)

Policy Changes

11.30.24policy revisionLatest

Revised desmopressin acetate (DDAVP) trial requirement to apply only for age ≥ 2 years; updated prophylaxis approval durations for Medicaid/HIM and Commercial and clarified continued therapy weight documentation; references updated.

09.25.25policy update

Added pediatric extension and expanded routine prophylaxis indication for Vonvendi; added step therapy bypass for Illinois HIM per IL HB 5395.

08.25.23policy update

Factor VIII/von Willebrand Factor Complex (Human Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant Vonvendi)

Medical Necessity Criteria

Relevant Billing Codes

Required Provider Actions and Billing Rules

Clinical Thresholds and Key Definitions

Clinical Background

Policies to Read With This Policy

Policy Changes